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Abstract 
High-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) is applied 
for consolidation in myeloma and relapsing lymphoma patients. Vitamin D (VitD) exerts effects 
during hematopoietic stem cell proliferation, differentiation and interactions with the immune 
system. VitD deficiency is frequent in patients with hematological malignancies, but its 
prognostic relevance after ASCT remains unclear. We investigated the effect of VitD serum 
levels in patients with lymphomas and myeloma at ASCT on progression-free (PFS) and 
overall survival (OS). The cohort (n=183) was divided in two groups: 81 (44%) had VitD levels 
>52 nmol/L and 102 (56%) ≤52 nmol/L at ASCT. VitD levels >52 nmol/L were associated with 
better PFS (p=0.0194) and OS (p=0.011). Similarly, when evaluating myeloma patients alone, 
patients with lower VitD levels (≤52 nmol/L) had inferior PFS (p=0.0412) and OS (p=0.049). 
Finally, the multivariate analysis was consistent that varying VitD levels were significantly 
associated with OS (p=0.0167), also when stratifying patients in groups with VitD levels > 
versus ≤52 nmol/L (p=0.0421). Our data suggest that reduced serum VitD levels in myeloma 
and lymphoma patients undergoing HDCT/ASCT are associated with inferior outcome. 
Optimizing VitD levels before ASCT may be warranted.  
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Introduction 
High-dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) is 
a frequent consolidation option for patients with various hematological malignancies1 including 
multiple myeloma (MM) and various lymphoma subtypes. A variety of factors were shown to 
be prognostically relevant for patients undergoing HDCT/ASCT, such as age, disease stage, 
presence of B-symptoms or extranodal manifestations,2,3 whereas the role of Vitamin D (VitD) 
serum levels is unclear in this setting.  
VitD is a fat-soluble vitamin, vastly acquired by endogenous production mediated following 
UVB radiation, which is highly relevant for regulation of calcium and phosphate homeostasis. 
25-hydroxyvitamin D3 is the main circulating metabolite and total 25-hydroxyvitamin D (25-
OH-D) reflects the VitD status.4 The biologically active form 1,25-hydroxy-VitD acts on the 
nuclear VitD receptor (VDR) and promotes intestinal calcium and phosphate absorption. VDRs 
are not only expressed in tissues involved in calcium homeostasis, but in many other tissues 
and cell types.4 There is growing evidence that vitamin D signaling is not restricted to cells 
involved in calcium homeostasis, but rather affect a variety of cellular processes such as 
proliferation, apoptosis, differentiation, angiogenesis and metastasis.4-10 Moreover, VitD 
metabolites were documented to exert various modulatory effects on the immune system.11 
Such pathways may also be of significance during and after HDCT with ASCT, even more so 
as VitD deficiency is frequent in the general population,12 and even more so in patients with 
hematological malignancies. In various studies, in between 30% and 80% of patients with 
different hematological malignancies and within different treatment settings were reported to 
show VitD serum levels less than 50 nmol/L,13-16  and around 50% of patients were reported to 
show serum levels less than 30 nmol/L.17  In addition, there is an ongoing debate on the ideal 
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threshold to define VitD deficiency, which is reflected by varying cutoffs among different 
studies. 
In solid tumors, the role of VitD has been extensively explored particularly with regards to its 
potential anti-cancer effects suggesting that VitD may inhibit carcinogenesis and can be 
associated with superior outcome in various solid tumors such as colorectal,18-20 prostate,21,22 
breast,23-25 bladder,26 ovarian,27,28 lung,29,30 and thyroid cancer31. In patients with hematological 
malignancies, higher VitD levels were reported to be associated with superior outcomes.13,15-
17,32-35 However, these studies were limited to patients undergoing allogeneic hematopoietic 
stem cell transplantation, and literature on VitD in the autologous transplant setting is 
scarce.6,36 Thus, the prognostic value of pre-transplant VitD levels has not been thoroughly 
investigated in the HDCT/ASCT setting in patients with hematological malignancies. In this 
study, we evaluated the effect of varying 25-OH-VitD levels at the time of ASCT on the clinical 
outcome in patients with multiple myeloma and various lymphomas.  
 
Material and Methods 
Patients and study design 
We analyzed all adult patients (≥18 years) with multiple myeloma and various lymphoma 
subtypes undergoing HDCT with ASCT between 03/2012 and 07/2018 at the University 
Hospital of Bern, Switzerland. Availability of vitamin D assessment on the day of hospital 
admission for high-dose chemotherapy (HDCT) before the ASCT was required for inclusion in 
the study. In patients with tandem transplantation procedures, the first ASCT was considered. 
Among the various VitD metabolites, only 25-OH-VitD was investigated as it primarily 
represents the VitD status and it is the predominant circulating metabolite. We collected data 
on clinical characteristics at diagnosis, treatment before ASCT, parameters related to 
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HDCT/ASCT and clinical outcomes. The local ethics committee of Bern, Switzerland, approved 
the study (decision number # 374/15). All patients gave written informed consent.  
 
Methods and definitions 
The cohort was subdivided into two groups depending on the 25-OH-VitD serum levels. This 
resulted in one group with 25-OH-VitD levels above 52 nmol/L (“normal VitD”) and a second 
group with 25-OH-VitD ≤52 nmol/L (“low VitD”). This cut-off was based on the Endocrine 
Society guidelines of defining VitD deficiency as <50 nmol/L, and VitD insufficiency as 52.5 – 
72.5 nmol/L.37 In accordance, this study investigated the impact of the pre-defined cut-off of 
52 nmol/L on survival rates after HDCT/ASCT.  
VitD was measured using the Liaison 25 Dihydroxyvitamin D total assay (DiaSorin, Stillwater, 
MN, USA). This assay is measuring total VitD (25-OH-VitD3 plus 25-OH-VitD2) as 
recommended by the Institute of Medicine 2011 guidelines.45 
 
Statistical analysis 
Primary endpoints of this study were PFS and OS of patients with VitD levels at HDCT/ASCT 
above versus below 52 nmol/L, and survival rates were calculated using the method of Kaplan 
and Meier. Log-rank test was performed in order to compare survival proportions and calculate 
p-values. Unpaired t-test was applied for the comparison of medians and continuous variables 
between the two groups. Categorical clinical characteristics were compared using Fisher’s 
exact test. The correlation of two variables was assessed using multivariable cox regression 
in the multivariate analysis, where the impact on PFS and OS of predictors such as VitD levels, 
gender, diagnosis, age, and remission status was assessed. P-values of less than 0.05 were 
considered to be significant. We calculated medians and totals by Microsoft Excel 2016. 
This article is protected by copyright. All rights reserved.
 
 
Eicher et al         Vitamin D levels affect outcome after ASCT 
GraphPad Prism 8 (GraphPad Software, La Jolla, CA) was applied to visualize Kaplan Meier 




During the study period, we identified 183 lymphoma and myeloma patients fulfilling the 
inclusion criteria. Within this cohort, 81 patients (44%) had 25-OH-VitD levels above 52 nmol/L 
(“normal VitD”), and 102 patients (56%) had VitD levels ≤52 nmol/L (“low VitD”). The clinical 
characteristics of both groups are summarized in Table 1. There was a male preponderance 
(70% of patients) within the entire cohort, with the proportion of males being even higher in the 
low VitD group as compared to the normal VitD group (77% versus 62%; p=0.0356). Probably 
due to this gender imbalance in both groups, the body weight was lower in the normal VitD 
group (median 70 kg versus 77 kg; p=0.0098). Whereas the proportion of patients in CR at the 
time of ASCT was comparable in the normal versus low VitD groups (16% vs. 23%; p=0.3497), 
more patients in the normal VitD group had PR (56% vs. 38%; p=0.025) and less patients had 
progressive disease (PD; 4% vs. 16%; p=0.0129). Otherwise, both groups were comparable 
for clinical characteristics at diagnosis and for disease subtypes and stage distribution.  
 
Chemotherapy regimens and transplant details 
The regimens used for induction and high-dose chemotherapy (HDCT) are given in Table 2.  
We found no differences between the normal and the low VitD groups concerning the various 
chemotherapeutic regimens. Induction regimens in myeloma patients were bortezomib-based 
(VRD with bortezomib, lenalidomide, dexamethasone, or VCD with bortezomib, 
cyclophosphamide, dexamethasone), whereas HDCT was melphalan-based. Lymphoma 
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patients predominantly received HDCT with B(e)EAM (bendamustine or BCNU, etoposide, 
cytarabine, melphalan). Furthermore, total numbers of transplanted CD34+ cells, intervals 
between ASCT and neutrophil recovery >0.5 G/L, and platelet recovery >20 G/L were 
comparable between both groups (Table 2). 
 
Survival outcomes 
The overall mortality was lower in the normal VitD group as compared to the low VitD group 
(14% versus 28%; p=0.0191). Mortality in the first two years was 10% in the normal VitD and 
25% in the low VitD group (p=0.0075).  
Figure 1 compares the survival outcomes of patients in the normal VitD (>52 nmol/L) group to 
those in the low VitD (≤52 nmol/L) group. The PFS was superior in the normal VitD group as 
compared to the low VitD group (median 19.3 months versus 14.3 months; p=0.0194). When 
the lymphoma patients were separately analyzed, PFS did not differ significantly between 
patients with normal and low VitD levels (p=0.251). In the myeloma patients, however, the PFS 
was longer in the normal VitD patients as compared to the low VitD patients (median 19.5 
months versus 16.0 months; p=0.0412).   
OS was superior in the normal VitD group (median 21.3 months versus 17.1 months; p=0.011). 
Again, OS did not differ significantly between normal and low VitD patients with lymphomas 
(p=0.1242), whereas significant differences were documented in the myeloma patients: 
Median OS was 21.4 months in patients with normal VitD as compared to 20.4 months in 
patients with low VitD  (p=0.049).  
 
Prognostic parameters 
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We investigated whether low VitD levels at the time of ASCT had an independent prognostic 
impact in a multivariate analysis depicted in Table 3. Other parameters in the multivariate 
analysis were patients’ age at the time of ASCT (as continuous parameter), gender, disease, 
and remission status at the time of ASCT.  
First, considering 25-OH-VitD levels as continuous variables, VitD levels were demonstrated 
to have an independent prognostic impact on overall survival (p=0.0167). With the increase of 
the VitD level by one unit (nmol/L), the risk of death was reduced by 2% (HR=0.98). 
Remarkably, none of the other variables included in the multivariate analysis was significantly 
associated with OS.  
Secondly, we stratified patients into the two groups with normal versus low VitD levels 
considering the above cut-off of 52 nmol/L. Again, this cut-off of VitD was the only parameter 
independently associated with OS (p=0.0427). The hazard ratio for death was 0.51 in patients 
with VitD levels above 52 nmol/L compared to patients with VitD levels below this cutoff. 
 
Discussion 
In patients with hematological malignancies undergoing hematopoietic stem cell 
transplantation, higher VitD levels were reported to be associated with superior outcomes. 13,15-
17,32-35 However, these studies were limited to patients undergoing allogeneic stem cell 
transplantation, and literature on VitD in ASCT is scarce.6,36 Thus, the prognostic value of pre-
transplant VitD levels has not been thoroughly investigated in in patients with hematological 
malignancies in the HDCT/ASCT setting, although HDCT/ASCT is a frequent consolidation 
option for patients with various hematological malignancies1 including myeloma and various 
lymphoma subtypes. 
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Thus, we prospectively determined VitD levels in a large cohort of 183 patients with myeloma 
and lymphoma before HDCT/ASCT and investigated the effect of VitD serum levels on the 
survival outcomes. In accordance with Endocrine Society guidelines, which defined VitD 
deficiency as <50 nmol/L and VitD insufficiency as 52.5 – 72.5 nmol/L,37 we applied a serum 
level of 52 nmol/L as threshold for our study.  
First, in accordance with previous studies clearly showing that VitD deficiency is common 
among patients with hematological malignancies,13-17,32-35 we found reduced 25-OH-D levels 
≤52 nmol/L in 56% of the patients in our cohort. Second, and even more important, we could 
clearly demonstrate that patients with reduced levels of VitD (≤52 nmol/L) had inferior PFS 
(median 14.3 months versus 19.3 months; p=0.0194) and OS group (median 17.1 months 
versus 21.3 months; p=0.011) as compared to patients with normal VitD levels (above the 
respective threshold). Moreover, we found a reduced VitD level to represent an independent 
negative prognostic parameter by multivariate analysis, whereas other parameters such as 
patients’ age at the time of ASCT, gender, disease (myeloma versus lymphoma), and 
remission status at the time of ASCT had no independent prognostic impact.  
“Sufficient” VitD levels have been associated with superior PFS and OS in patients with various 
solid tumors (colorectal,18-20 prostate,21,22 breast,23-25 bladder,26 ovarian,27,28 lung,29,30 thyroid 
cancer)31 and hematological malignancies13,15-17,32-35 in previous reports. Nevertheless, VitD 
serum level is a general and unspecific marker indicating overall health and nutritional status, 
and VitD deficiency has been associated with inferior OS also in the general population.38 VitD 
levels were also reported to be prognostically relevant for the outcomes after allogeneic 
hematopoietic stem cell transplantation in patients with various hematological 
malignancies.4,5,13,14,39,40 The results of our study in accordance with a limited number of 
This article is protected by copyright. All rights reserved.
 
 
Eicher et al         Vitamin D levels affect outcome after ASCT 
previous studies by others referring to ASCT6,36 suggest that the prognostic value of VitD levels 
is also operational in patients undergoing HDCT/ASCT. 
In our study, the benefit of normal VitD levels was more evident in myeloma than in lymphoma 
patients. This may be due to the fact that HDCT/ASCT is a standard consolidation for myeloma 
patients as part of first-line treatment, whereas its role for lymphoma patients is more 
heterogeneous.   
The role of VitD metabolites for immune system modulation and hematopoietic cell 
differentiation is well established:4-11 The VitD-receptor (VDR) is expressed on various 
precursor cells in the hematopoietic system. VDR-mediated effects include promotion of 
differentiation, apoptosis and growth inhibition, which are also involved during the development 
of hematological malignancies. Accordingly, low VitD levels have been associated with greater 
clonal proliferation in leukemic cells.33 VDR activation can also trigger differentiation and 
thereby enhance the numbers of mature cells.4,7 Thus, VRD-mediated mechanisms may also 
contribute to differences in outcome after specific cancer treatment such as HDCT/ASCT.  
VDR-signaled effects may modulate cell differentiation in various stages of hematopoiesis. 
VitD analogues have been shown to promote apoptosis and cell cycle arrest in myeloma 
cells.41-43 Furthermore, inhibition of proliferation in lymphoma cell lines was achieved following 
VitD supplementation in murine models.44 In summary, patients with normal VitD levels may 
benefit from these VDR-mediated mechanisms at various stages of the course of their disease.  
With regards to eventual therapeutic intervention, there is an ongoing debate on how much 
VitD is required to exert its effects on cell differentiation and immune modulation. It has also 
been suggested that these levels may range in supra-physiologic concentrations to generate 
immune responses, causing at the same time relevant complications such as 
hypercalcemia.7,9,10 Furthermore, low VitD serum levels in principle could identify specific risk 
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groups in patients with hematological or solid malignancies, and the supplemental correction 
of reduced VitD serum levels does not necessarily compensate the apparent adverse 
prognostic association of low VitD levels in these patients.  
This study analyzed a patient cohort undergoing HDCT with ASCT between 2012 and 2018. 
Despite the obvious limitations of a retrospective study covering such a long period, 
considerable heterogeneity concerning disease subtypes, pretreatment, remission status, type 
of HDCT, and subsequent treatment after ASCT, we identified a significant association of VitD 
levels >52 nmol/L at the time of HDCT with ASCT with superior outcomes. This association 
was most evident in the myeloma patients but was documented as well in the patients with 
lymphomas. Consequently, it is tempting to recommend correcting low VitD levels at 
HDCT/ASCT, particularly since this is a rather inexpensive and easy intervention with a 
favorable toxicity profile. Prospective interventional studies should be initiated to explore the 
efficacy of such strategy in a larger, randomized, and prospective setting.  
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Tables  
 
Table 1: Comparison of clinical characteristics at diagnosis in 183 patients undergoing HDCT/ ASCT 
with 25-OH-D levels above versus below 52 nmol/L.  
 
 “Exact Fisher’s test” and “unpaired t-test” were applied to calculate p-values. Abbreviations: 25-OH-D: 25-
hydroxyvitamine D serum level; (R-ISS): (Revised) Multiple Myeloma International Staging System; NHL: Non-
Hodgkin lymphoma; DLBCL: diffuse large B-cell lymphoma; MCL: mantle cell lymphoma; FCL: follicle center 
lymphoma; CNSL: central nervous system lymphoma; TCL: T-cell lymphoma; IPI: International Prognostic Index; 
CR: complete remission; VGPR: very good partial remission; PR: partial remission; SD: stable disease; PD: 
progressive disease. ¹6 patients staged by R-ISS instead of ISS. ²Percentage values of B symptoms refer to the 
total of stage I, II, III and IV. 
 
  
Parameter 25-OH-D serum level  
 >52 nmol/L ≤52 nmol/L p 
Number of patients (%) 81 (44) 102 (56) - 
Males/females (ratio) 50/31 (1.6) 78/24 (3.2) 0.0356 
25-OH-D, nmol/L, median (range) 68 (53-123) 35¹ (<12-52) - 
Age at ASCT, median (range) 61 (24-74) 60 (25-77) 0.5555 
Body weight at ASCT, kg, median (range) 70 (43-116) 77 (46-122) 0.0098 
Multiple myeloma (n=104) n (%) 
ISS¹ I   n (%) 
 II   n (%) 













Hodgkin’s disease (n=1) n (%) 
NHL (n=78)   n (%) 
 DLBCL   n (%) 
 MCL   n (%) 
 FCL   n (%) 
 CNSL   n (%) 
 TCL   n (%) 
 Others   n (%) 
 
Stage I   n (%) 
 II   n (%) 
 III   n (%) 
 IV   n (%) 
 unknown  n (%) 
 B symptoms²  n (%) 
 
IPI 0-1    n (%) 
 2    n (%) 
 3    n (%) 
 4-5    n (%) 
































































Remission status at ASCT 
 CR    n (%) 
 VGPR    n (%) 
 PR    n (%) 
 SD    n (%) 
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Table 2: Clinical characteristics of patients with 25-OH-D levels above versus below 52 nmol/L 

















Exact Fisher’s test and unpaired t-test were applied to calculate p-values. VRD: velcade (bortezomib), 
revlimid (lenalidomide), dexamethasone; VCD: bortezomib, cytarabine, dexamethasone; VD: bortezomib, 
dexamethasone; (R-)DHAP: rituximab, dexamethasone, high-dose cytarabine, cisplatin; (R-)CHOP: 
rituximab, cyclophosphamide, oncovin (vincristin), predniso(lo)ne; (R-)CHOEP: + etoposide; MATRix: 
methotrexate, cytarabine, thiotepa, rituximab; R-DA-EPOCH: dose-adjusted rituximab, etoposide, 
prednisolone, oncovin, cyclophosphamide, hydroxydaunorubicin; Ben/Mel: bendamustine, melphalan; 
BEAM: carmustine, etoposide, cytarabine, melphalan; BeEAM: bendamustine, etoposide, cytarabine, 
melphalan; b.w.: body weight; ANC: absolute neutrophil count. 
 
  
Parameter 25-OH-D serum level  
 >52 nmol/L ≤52 nmol/L p 
Induction chemotherapy regimen 
 VRD   n (%) 
 VCD   n (%) 
 VD   n (%) 
 (R)-DHAP  n (%) 
 (R)-CHOP  n (%) 
 (R)-CHOEP  n (%) 
 R-CHOP and R-DHAP n (%) 
 MATRix  n (%) 
 R-DA-EPOCH  n (%) 


































High-dose chemotherapy regimen 
 Melphalan   n (%) 
 Ben/Mel  n (%) 
 BEAM   n (%) 
 BeEAM   n (%) 


























Days until ANC >0.5 G/L, median 11 11 0.5035 
Days until platelets >20 G/L, median 13 14 0.2736 
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1Multivariable cox regression with OS as a dependent variable and vitamin D as a continuous independent variable. 
2Multivariable cox regression with OS as a dependent variable and patients stratified in two groups according to the 
median vitamin D serum level (>52 vs. ≤52 nmol/L). CI: confidence interval; CR: complete remission; VGPR: very 




Overall survival1 Overall survival2 
Hazard ratio 
(95% CI) 
p Hazard ratio 
(95% CI) 
p 
Gender (male vs. female) 1.37 (0.66-2.94) 0.4041 1.55 (0.74-3.33) 0.239 
Category (myeloma vs. lymphoma) 0.59 (0.30-1.18) 0.1349 0.64 (0.3-1.24) 0.171 
Age 1.01 (0.97-1.07) 0.4007 1.01 (0.97-1.06) 0.8902 
Remission (CR/VGPR vs. PR/SD/PD) 0.87 (0.42-1.88) 0.6980 0.67 (0.36-1.38) 0.294 
25-OH-D level 0.98 (0.97-1.00) 0.0167 0.51 (0.26-0.98) 0.0421 
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